1. Beal, S. L., & Sheiner, L. B. (1992). NONMEM user’s guide. San Francisco: NONMEM Project Group, University of California, San Francisco.
2. Bhattaram, V. A., Booth, B. P., Ramchandani, R. P., Beasley, B. N., Wang, Y., Tandon, V., et al. (2005). Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. American Association of Pharmaceutical Scientists Journal, 7, E503–E5122005.
3. Biomarkers Definition Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69(3), 89–95.
4. Burman, C. F., Hamren, B., & Olsson, P. (2005). Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics, 4(1), 47–58.
5. Chabaud, S., Girard, P., Nony, P., & Boissel, J. P. (2002). Clinical trial simulation using therapeutic effect modeling: Application to ivabradine efficacy in patients with angina pectoris. Journal of Pharmacokinetics and Pharmacodynamics, 29, 339–363.